Clinical Efficacy and Safety of Naftopidil Treatment for Patients with Benign Prostatic Hyperplasia and Hypertension: A Prospective, Open-Label Study

키워드

참고문헌 (26)

1. Boyle P, "The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension", Scand J Urol Nephrol Suppl, 168, pp.7~12 (1995)
2. Parsons JK, "Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems", J Urol, 178, pp.395~401 (2007)
3. Lee SH, "Effects of α-blocker ‘add on’treatment on blood pressure in symptomatic BPH with or without concomitant hypertension", Prostate Cancer Prostatic Dis, 13, pp.333~337 (2010)
4. Fawzy A, "Long-term (4 year) efficacy and tolerability of doxazosin for the treatment of concurrent benign prostatic hyperplasia and hypertension", Int J Urol, 6, pp.346~354 (1999)
5. Chung BH, "Long-term follow-up study to evaluate the efficacy and safety of the doxazosin gastrointestinal therapeutic system in patients with benign prostatic hyperplasia with or without concomitant hypertension", BJU Int, 97, pp.90~95 (2006)
6. McConnell JD, "The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia", N Engl J Med, 349, pp.2387~2398 (2003)
7. Kirby RS, "Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia:the Prospective European Doxazosin and Combination Therapy (PREDICT) trial", Urology, 61, pp.119~126 (2003)
8. Takei R, "Naftopidil, a novel alpha1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha1-adrenoceptors", Jpn J Pharmacol, 79, pp.447~454 (1999)
9. Gotoh M, "Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial", BJU Int, 96, pp.581~586 (2005)
10. Nishino Y, "Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study", BJU Int, 97, pp.747~751 (2006)
11. Perumal C, "A comparison of the efficacy of naftopidil and tamsulosin hydrochloride in medical treatment of benign prostatic enlargement", Urol Ann, 7, pp.74~78 (2015)
12. Komiya A, "Clinical effect of naftopidil on the quality of life of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia:a prospective study", Int J Urol, 17, pp.555~562 (2010)
13. Chobanian AV, "Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure", Hypertension, 42, pp.1206~1252 (2003)
14. Cifkova R, "Practice guidelines for primary care physicians: 2003 ESH", ESC hypertension guidelines, 2003, pp.21, 1779~1786
15. Kirby RS, "Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men", Urology, 46, pp.182~186 (1995)
16. Kaplan SA, "Doxazosin in physiologically and pharmacologically normotensive men with benign prostatic hyperplasia", Urology, 46, pp.512~517 (1995)
17. Himmel HM, "Naftopidil, a new alpha-adrenoceptor blocking agent with calcium antagonistic properties:characterization of Ca2+ antagonistic effects", J Cardiovasc Pharmacol, 17, pp.213~221 (1991)
18. Sponer G, "Naftopidil, a new adrenoceptor blocking agent with Ca(2+)-antagonistic properties: interaction with adrenoceptors", J Cardiovasc Pharmacol, 20, pp.1006~1013 (1992)
19. Grundke M, "Characterization of Ca(2+)-antagonistic effects of three metabolites of the new antihypertensive agent naftopidil, (naphthyl)hydroxy-naftopidil, (phenyl)hydroxy-naftopidil, and O-desmethyl-naftopidil", J Cardiovasc Pharmacol, 18, pp.918~925 (1991)
20. Sugaya K, "Effects of intrathecal injection of tamsulosin and naftopidil, alpha-1A and -1D adrenergic receptor antagonists, on bladder activity in rats", Neurosci Lett, 328, pp.74~76 (2002)
21. Utsunomiya N, "A crossover comparison study on lower urinary tract symptoms with overactive bladder secondary to benign prostatic hyperplasia: naftopidil versus tamsulosin with solifenacin", Hinyokika Kiyo, 62, pp.341~347 (2016)
22. Sakai H, "Efficacy of naftopidil in patients with overactive bladder associated with benign prostatic hyperplasia: prospective randomized controlled study to compare differences in efficacy between morning and evening medication", Hinyokika Kiyo, 57, pp.7~13 (2011)
23. Oh-oka H, "Effect of naftopidil on nocturia after failure of tamsulosin", Urology, 72, pp.1051~1055 (2008)
24. Hampel C, "Modulation of bladder alpha1-adrenergic receptor subtype expression by bladder outlet obstruction", J Urol, 167, pp.1513~1521 (2002)
25. Schwinn DA, "The role of alpha1-adrenergic receptor subtypes in lower urinary tract symptoms", BJU Int, 88(Suppl 2), pp.27~34 (2001)
26. Malloy BJ, "Alpha1-adrenergic receptor subtypes in human detrusor", J Urol, 160(3 Pt 1), pp.937~943 (1998)

관련 논문AI추천